I was there as well. Very open and transparent presentation with explanation of what happened over the past year with the challenges of receiving CE mark with BSI and where we are at currently. Dr Chris Roberts chaired the formal part of the AGM then Daniel Kenny presented with Q&A at the end. Meeting finished around 12.30pm. 90 minute meeting.
Presentation was elaborated upon in laymen’s language. Bottom line is that Oncosil has achieved groundbreaking results for treatment of pancreatic cancer and it works. Beats any other treatment that’s been done in the past anywhere in the world. One interesting point mentioned was that overall survival (OS) is currently at 16 months but has the potential to increase as the 2 year trial period has not ended yet.
Board of directors seemed confident of a positive result from BSI. Patience needed once again. Almost there in my opinion.
Best wishes for all the patient investors.
OSL Price at posting:
12.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)